Biorestorative Therapies, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BioRestorative Therapies reported a significant net loss and negative cash flow for 2025, raising substantial doubt about its ability to continue as a going concern, despite clinical progress and recent capital raises.
NASDAQ
10-K: BioRestorative Therapies Issues 10-K Filing, Outlines Progress in Disc/Spine and ThermoStem Programs
BioRestorative Therapies files its 10-K, highlighting clinical trial progress, financial results, and future plans in cell therapy.
NASDAQ
BioRestorative Therapies, Inc. filed an amendment to its annual report to include a description of its securities and anti-takeover provisions.
NASDAQ
BioRestorative Therapies restated its past financial statements due to a misapplication of accounting guidance related to warrants, leading to the identification of a material weakness in internal controls.
NASDAQ
BioRestorative Therapies has granted stock options to an executive and a board member as part of their compensation packages.